Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
Public ClinicalTrials.gov record NCT00413790. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 3-Way Cross-Over, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Pharmacologic Effects of a 7-Day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d on Cardiovascular Parameters in Healthy Subjects 50 Years of Age and Older
Study identification
- NCT ID
- NCT00413790
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Novartis
- Industry
- Enrollment
- 162 participants
Conditions and interventions
Conditions
Interventions
- Darifenacin Drug
- Tolterodine Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2006
- Primary completion
- Not listed
- Completion
- Aug 31, 2007
- Last update posted
- Jan 14, 2008
2006 – 2007
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | Scottsdale | Arizona | 85251 | — |
| Investigative Site | Tempe | Arizona | 85282 | — |
| Investigative Site | San Diego | California | 92103 | — |
| Investigative Site | Jacksonville | Florida | 32216 | — |
| Investigative Site | Jupiter | Florida | 33458 | — |
| Investigative Site | Overland Park | Kansas | 66215 | — |
| Investigative Site | Madisonville | Kentucky | 42431 | — |
| Investigative Site | Wellesley Hills | Massachusetts | 02481 | — |
| Investigative Site | Hackensack | New Jersey | 07601 | — |
| Investigative Site | Buffalo | New York | 14202 | — |
| Investigative Site | Austin | Texas | 78752 | — |
| Investigative Site | Dallas | Texas | 75235 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00413790, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 14, 2008 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00413790 live on ClinicalTrials.gov.